Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.

Trial Profile

Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 14 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 10 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top